Method for producing Hib conjugate vaccine using PRP with lowered molecular weight
A method for preparing a PRP conjugate having high storage stability and a method for producing a Hib conjugate vaccine are provided. A method for preparing PRP conjugate in accordance with the embodiments of the present invention is characterized by that the release of PRPs after preparing the PRP conjugate is suppressed by using PRP with a lowered molecular weight than native PRP for a coupling reaction between PRP and a carrier protein. Also, a Hib conjugate vaccine comprising as an antigen the PRP conjugate prepared by said method has excellent storage stability and maintain sufficient immunogenicity.
1. A method for preparing a polyribosylribitol phosphate (PRP) conjugate via a coupling reaction of PRP and a carrier protein wherein the method is characterized by that the release of PRPs after preparing the PRP conjugate is suppressed by using PRP with a lowered molecular weight than native PRP, wherein the PRP conjugate is stored in a solution of pH 5.4 to 6.3 after preparation of the PRP conjugate.
2. The method of claim 1 wherein a released amount of PRPs in a stress test in a solution at pH 5.4 to 6.3 at 37° C. for 4 weeks is less than 50%.
3. The method of claim 1 wherein PRP with a lowered molecular weight is obtained by physical fracture.
4. The method of claim 1 wherein PRP with a lowered molecular weight is obtained by hydrolysis with an acid or an alkali.
5. The method of claim 1 wherein PRP with a lowered molecular weight has a molecular weight of 80 to 150 kDa.
6. The method of claim 1 wherein PRP and the carrier protein is subject to the coupling reaction for preparing the PRP conjugate at a weight ratio of from 2:1 to 4.1.
7. The method of claim 6 wherein PRP and the carrier protein are subject to the coupling reaction at a weight ratio of 4:1.
8. The method of claim 1 wherein the method comprises a step of activating PRP with a lowered molecular weight using 1-cyano-4-(dimethylamino) pyridinium tetrafluoroborate (CDAP) before the coupling reaction for preparing the PRP conjugate.
9. The method of claim 1 wherein the carrier protein is tetanus toxoid.
10. The method of claim 9 wherein a purity of tetanus toxoid is 2,500 to 3,500 LF/mg PN.
11. The method of claim 10 wherein a purity of tetanus toxoid is 2,900 to 3,300 LF/mg PN.
12. A method for producing a Haemophilus influenzae type b (Hib) conjugate vaccine comprising the method as set forth in claim 1 .